Should I buy Summit Therapeutics stock in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Summit Therapeutics for over three years. Every month, hundreds of thousands of users in Singapore trust us to analyse market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Summit Therapeutics.

What is Summit Therapeutics?

The Summit Therapeutics Stock Price

The price of Summit Therapeutics stock is rising this week. The current share price stands at $24.55, showing an increase of $1.93 (+8.53%) over the past 24 hours and a jump of 15.15% for the week. Market capitalization is now $18.23 billion, with a three-month average trading volume of 5.2 million shares. The company has no reported P/E ratio due to operating losses, pays no dividend, and has a stock beta of -1.02. Summit Therapeutics has shown swift recent growth, but investors should be mindful of potential volatility in this biotech sector.

Our full analysis on the Summit Therapeutics stock

After a rigorous review of Summit Therapeutics’s most recent financial results and a detailed examination of the stock’s impressive multi-year trajectory, our analysis integrates current financial indicators, technical market signals, and sector benchmarking data—leveraging proprietary algorithms developed for superior accuracy. Inputs from competitor monitoring and top-tier market research firms ensure a comprehensive perspective. So, why might Summit Therapeutics stock once again become a strategic entry point into the fast-evolving biotech sector in 2025?

Recent performance and market context

Summit Therapeutics has delivered a spectacular price performance, with its stock trading at $24.55 as of July 2025—up 8.53% over 24 hours, 15.15% for the week, and an exceptional 256% over the last year. This momentum is buoyed by standout events, including the announcement of positive Phase III results from the HARMONi study, which showed statistically significant improvement in progression-free survival for its flagship drug, ivonescimab. Industry optimism is reinforced by a dynamic partnership pipeline with leading pharmaceutical players (AstraZeneca, Revolution Medicines, Pfizer), strategically positioning Summit at the center of next-generation oncology therapies. The biotech sector, especially in innovative immunotherapy, continues to attract global investor interest, as strong regulatory flows and growing healthcare demand provide a fertile context for future revenue.

Technical analysis

The technical setup for Summit Therapeutics has reached increasingly bullish territory. The RSI (14 days) sits at a healthy 62.64, maintaining neutrality with upside room, while the MACD (12,26,9) delivers a positive signal (+0.49), confirming continued momentum. Price action remains robust above key moving averages (20-, 50-, and 200-day), signifying short- and medium-term strength. Current price levels outperform all major support zones, particularly the $20.91–$21.47 range, underpinning a strong technical base. Near-term resistance at $26.80 comes into view, but the absence of significant selling pressure and the prevalence of buy signals (over 90% of relevant technical indicators) underscore a strong bullish potential. This favorable configuration and above-average trading volumes highlight a market poised for an additional upward breakout.

Fundamental analysis

From a fundamental perspective, Summit Therapeutics stands out for its clinical and strategic milestones. While the company remains pre-revenue as of Q1 2025—typical among innovative biotech firms—its net loss narrowed to $62.9 million for the quarter, beating expectations and providing evidence of disciplined resource management. Summit’s market cap of $18.23 billion accurately reflects investor enthusiasm for its pipeline leadership, especially after outperforming clinical results for ivonescimab, which targets dual immune checkpoints (PD-1 and VEGF). Despite the absence of a conventional P/E ratio, the company’s compelling growth narrative is reinforced by a robust balance sheet with $361.3 million in cash, an expanding patent portfolio, and a differentiated business model focused on late-stage drug candidates in high-value indications. With industry-leading partnerships, a strong position in oncology immunotherapy, and disciplined execution, Summit’s fundamentals justify renewed and serious investor attention.

Volume and liquidity

Trading liquidity is another pillar supporting the investment case for Summit Therapeutics. With an average daily volume of 5.2 million shares over the past three months, the stock enjoys substantial participation from institutional and retail investors alike. This high trading velocity helps ensure efficient price discovery and reduces slippage risk, making the stock a reliable vehicle for both entry and exit, regardless of position size. The available float and dynamic volume trends suggest robust market confidence, a key ingredient for sustained value re-rating.

Catalysts and positive outlook

Looking ahead, Summit’s upward trajectory is fueled by clear and actionable catalysts. The most significant include ivonescimab’s pending regulatory path in non-small cell lung cancer, with strong Phase III data positioning the company for potential near-term approval and commercialization. Strategic collaborations with AstraZeneca (valued up to $15 billion) and Pfizer further extend the addressable markets and create avenues for synergy through co-development and licensing. On the innovation front, Summit’s proven ability to deliver on critical R&D milestones, together with a disciplined approach to patent management, strengthens its competitive moat. The sheer scale of the oncology market, persistent demand for next-generation immunotherapies, and Summit’s prominent profile in global clinical research provide ample reasons to maintain an optimistic outlook. Sector tailwinds, such as favorable regulatory conditions and increased healthcare spending across Southeast Asia, add to the compelling long-term narrative.

Investment strategies

For investors considering a position in Summit Therapeutics, the current technical and fundamental profile seems to represent an excellent opportunity. Short-term entry strategies can target technical support levels near $21 for swing trades ahead of anticipated news—such as conference presentations or regulatory filings. For medium-term positioning, holding through requisite clinical and regulatory catalysts linked to ivonescimab offers exposure to potential value inflection. Long-term investors are poised to benefit from Summit’s diversified pipeline, strong strategic partnerships, and the growing global appetite for breakthrough oncology solutions. Portfolio integration is further justified for Singapore-based investors seeking exposure to the US healthcare innovation space, as Summit’s liquidity, visibility, and fundamental strengths offer platform reliability and upward convexity.

Is it the right time to buy Summit Therapeutics?

Summit Therapeutics’s remarkable market performance, coupled with bullish technical and fundamental signals, seems to justify renewed interest among investors. The stock’s unprecedented appreciation, high conviction among analysts, and robust pipeline offer a strong combination of liquidity, innovation, and market leadership. Looking ahead, clinical catalysts and strong sector demand point to continued upside, making Summit Therapeutics a compelling addition for those seeking growth in an increasingly competitive biotech landscape. While all stocks require due diligence, the balance of risk and opportunity in Summit’s current setup signals that it may be entering a new bullish phase, and serious consideration is warranted.

Summit Therapeutics stands out as an innovative player whose pipeline strength, technical momentum, and market confidence may well mark it as a strategic opportunity in 2025 for investors in Singapore and beyond.

How to buy Summit Therapeutics stock in Singapore?

Buying Summit Therapeutics stock online is simple and secure when you use a regulated broker in Singapore. You can choose between classic spot buying—holding the shares in your account—or trading via CFDs (Contracts for Difference), which allows you to take advantage of price movements with leverage. Each method suits different investor objectives and risk profiles. For help choosing the right service, you’ll find a broker comparison tool further down this page.

Spot buying

A cash purchase means you buy and own real Summit Therapeutics shares, typically held in your brokerage account. Most brokers charge a modest fixed commission per order—usually around SGD $5. This approach is straightforward, with no leverage involved, making it ideal for long-term investors.

Gain scenario

For example: If the Summit Therapeutics share price is $24.55 USD, you can buy around 40 shares with a $1,000 stake, including a brokerage fee of around $5.

If the share price rises by 10%, your shares are now worth $1,100.

Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFD (Contract for Difference) trading lets you speculate on Summit Therapeutics share price movements without owning the underlying shares. Instead, you pay a spread (the difference between buy and sell price) and may incur overnight financing costs if you hold positions beyond a day. CFDs allow for leverage, meaning you can amplify your exposure—though gains and losses are both amplified.

Gain scenario

For example: You open a CFD position on Summit Therapeutics shares, with 5x leverage and a $1,000 investment.

This gives you a market exposure of $5,000.

If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a stake of $1,000 (excluding fees).

Final advice

Before investing in Summit Therapeutics, it’s essential to compare broker fees, commissions, spreads, and available features. The right choice depends on your investment objectives—whether you prefer straightforward share ownership or seek higher potential returns with leverage. Use the broker comparison further down the page to find the best fit for your needs.

Our 7 tips for buying Summit Therapeutics stock

The latest news about Summit Therapeutics

Summit Therapeutics stock surged 8.53% intraday and 15.15% over the past week on strong market momentum. This performance underscores accelerating global investor confidence in the company’s oncology pipeline, highlighted by a significant increase in average trading volume to 5.2 million shares daily and a market capitalisation of USD 18.23 billion as of July 3, 2025.

The company announced promising results from its Phase III HARMONi trial in non-small cell lung cancer in late June. These positive clinical outcomes, indicating a statistically significant improvement in progression-free survival, have reinforced the strategic positioning of Summit Therapeutics as an innovative leader in oncology and are highly relevant to Singapore’s strong biopharmaceutical investment community.

Summit Therapeutics secured a new clinical collaboration with Revolution Medicines this week to explore RAS inhibitor combinations using ivonescimab. This partnership signals expanding research opportunities in Asia-Pacific, opening doors for potential regional trials and elevating Singapore’s prospects as a hub for cutting-edge cancer therapies.

The analyst consensus remains “Strong Buy,” with a new median price target set at USD 34.33—nearly 40% above current levels. Optimistic analyst sentiment reflects strong commercial potential for Summit Therapeutics’ lead assets, which may attract further institutional attention from Southeast Asian investors seeking high-growth healthcare equities.

Summit Therapeutics maintains a healthy cash position of USD 361.3 million, supporting ongoing R&D and international expansion. Solid financial resources reassure Singapore’s investment market of the company’s ability to fund future clinical programs and cross-border collaborations, reinforcing its commitment to innovation and long-term sector leadership.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.